Skip to main content

FDA Approves Third Wave s PGx Test for Camptosar Adverse Events

NEW YORK, Aug. 24 (GenomeWeb News) - Third Wave this week received approval from the US Food and Drug Administration for a pharmacogenetic test that takes advantage of the recent re-labeling of a lucrative chemotherapy drug.

 

Third Wave claimed that its test is "the first pharmacogenetic test to be approved by the FDA for use as a companion diagnostic to a specific drug therapy," in a statement.

 

According to Third Wave, the FDA has cleared its Invader UGT1A1 molecular assay for use in identifying patients who may be at increased risk of adverse reaction to Pfizer's Camptosar, a chemotherapy drug for colorectal cancer.

 

The assay detects and identifies mutations in the UGT1A1 gene associated with that risk, and takes advantage of a recent re-labeling of Camptosar, which now includes dosing recommendation based on the patient's genetic profile.

 

Camptosar brought Pfizer first-quarter 2004 revenue of $212 million, up 132 percent compared to the same period in 2004, according to a statement from Pfizer. Sales in the United States account for about half of the drug's worldwide sales, Pfizer said.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.